Galera Therapeutics (Galera Therapeutics) Debt-to-Equity : -0.01 (As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Galera Therapeutics Debt-to-Equity?

Galera Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.13 Mil. Galera Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $1.12 Mil. Galera Therapeutics's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $-131.19 Mil. Galera Therapeutics's debt to equity for the quarter that ended in Dec. 2023 was -0.01.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Galera Therapeutics's Debt-to-Equity or its related term are showing as below:

GRTX' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.01 Med: 0 Max: 0.09
Current: -0.01

During the past 7 years, the highest Debt-to-Equity Ratio of Galera Therapeutics was 0.09. The lowest was -0.01. And the median was 0.00.

GRTX's Debt-to-Equity is not ranked
in the Biotechnology industry.
Industry Median: 0.15 vs GRTX: -0.01

Galera Therapeutics Debt-to-Equity Historical Data

The historical data trend for Galera Therapeutics's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Galera Therapeutics Debt-to-Equity Chart

Galera Therapeutics Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.01

0.09

-0.01

Galera Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															-	-	-0.01	-0.01	-0.01

Competitive Comparison of Galera Therapeutics's Debt-to-Equity

For the Biotechnology subindustry, Galera Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Galera Therapeutics's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Galera Therapeutics's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Galera Therapeutics's Debt-to-Equity falls into.

Galera Therapeutics Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Galera Therapeutics's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.133	+	1.117)	/	-131.185
	=	-0.01

Galera Therapeutics's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.133	+	1.117)	/	-131.185
	=	-0.01

Galera Therapeutics (NAS:GRTX) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Galera Therapeutics Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Galera Therapeutics's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Galera Therapeutics (Galera Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Galera Therapeutics Inc (NAS:GRTX) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

P.O. Box 134, Malvern, PA, USA, 19355

Website

https://www.galeratx.com

Galera Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer. Its lead product candidate, GC4419, is a small molecule dismutase mimetic developed for the reduction of severe oral mucositis, or SOM.

Executives

Mark Bachleda	officer: Chief Commercial Officer	C/O GALERA THERAPEUTICS, INC., 2 W LIBERTY BOULEVARD, #110, MALVERN PA 19355
Chris Degnan	officer: Chief Financial Officer	C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380
Mel Sorensen	director, officer: President and CEO	7 RAPPS RUN DRIVE, MALVERN PA 19355
Eugene P. Kennedy	officer: Chief Medical Officer	2503 SOUTH LOOP DRIVE, AMES IA 50010
Linda West	director	C/O GALERA THERAPEUTICS, INC., 2 W LIBERTY BLVD., #110, MALVERN PA 19355
Jennifer Evans Stacey	officer: See Remarks	AUXILIUM PHARMACEUTICALS, INC., 160 WEST GERMANTOWN PIKE, NORRISTOWN PA 19401
Jon T Holmlund	officer: Chief Medical Officer
Lawrence M Alleva	director	1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451
Novo Holdings A/s	10 percent owner, other: SEE REMARKS	TUBORG HAVNEVEJ 19, HELLERUP G7 2900
Joel F. Sussman	officer: Chief Accounting Officer	C/O GALERA THERAPEUTICS, INC., 2 W LIBERTY BLVD. #110, MALVERN PA 19355
Novartis Bioventures Ltd	10 percent owner	C/O NOVARTIS INTERNATIONAL AG, WSJ-200.220, CH-4002 BASEL V8 0000000000
New Enterprise Associates 14, L.p.	10 percent owner	1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Clarus Iv-a, L.p.	10 percent owner	101 MAIN STREET, SUITE 1210, CAMBRIDGE MA 02142
Blackstone Clarus Gp L.p.	10 percent owner	C/O THE BLACKSTONE GROUP INC., 345 PARK AVENUE, NEW YORK NY 10154
Sofinnova Venture Partners Ix, L.p.	10 percent owner	3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025